Cargando…
Statistical Modeling for Quality Risk Assessment of Clinical Trials: Follow-Up at the Era of Remote Auditing
BACKGROUND: As investigator site audits have largely been conducted remotely during the COVID-19 pandemic, remote quality monitoring has gained some momentum. To further facilitate the conduct of remote quality assurance (QA) activities for clinical trials, we developed new quality indicators, build...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8906112/ https://www.ncbi.nlm.nih.gov/pubmed/35262899 http://dx.doi.org/10.1007/s43441-022-00388-y |
_version_ | 1784665337028935680 |
---|---|
author | Koneswarakantha, Björn Ménard, Timothé |
author_facet | Koneswarakantha, Björn Ménard, Timothé |
author_sort | Koneswarakantha, Björn |
collection | PubMed |
description | BACKGROUND: As investigator site audits have largely been conducted remotely during the COVID-19 pandemic, remote quality monitoring has gained some momentum. To further facilitate the conduct of remote quality assurance (QA) activities for clinical trials, we developed new quality indicators, building on a previously published statistical modeling methodology. METHODS: We modeled the risk of having an audit or inspection finding using historical audits and inspections data from 2011 to 2019. We used logistic regression to model finding risk for 4 clinical impact factor (CIF) categories: Safety Reporting, Data Integrity, Consent and Protecting Endpoints. RESULTS: We could identify 15 interpretable factors influencing audit finding risk of 4 out of 5 CIF categories. They can be used to realistically predict differences in risk between 25 and 43% for different sites which suffice to rank sites by audit and inspection finding risk. CONCLUSION: Continuous surveillance of the identified risk factors and resulting risk estimates could be used to complement remote QA strategies for clinical trials and help to manage audit targets and audit focus also in post-pandemic times. |
format | Online Article Text |
id | pubmed-8906112 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-89061122022-03-09 Statistical Modeling for Quality Risk Assessment of Clinical Trials: Follow-Up at the Era of Remote Auditing Koneswarakantha, Björn Ménard, Timothé Ther Innov Regul Sci Analytical Report BACKGROUND: As investigator site audits have largely been conducted remotely during the COVID-19 pandemic, remote quality monitoring has gained some momentum. To further facilitate the conduct of remote quality assurance (QA) activities for clinical trials, we developed new quality indicators, building on a previously published statistical modeling methodology. METHODS: We modeled the risk of having an audit or inspection finding using historical audits and inspections data from 2011 to 2019. We used logistic regression to model finding risk for 4 clinical impact factor (CIF) categories: Safety Reporting, Data Integrity, Consent and Protecting Endpoints. RESULTS: We could identify 15 interpretable factors influencing audit finding risk of 4 out of 5 CIF categories. They can be used to realistically predict differences in risk between 25 and 43% for different sites which suffice to rank sites by audit and inspection finding risk. CONCLUSION: Continuous surveillance of the identified risk factors and resulting risk estimates could be used to complement remote QA strategies for clinical trials and help to manage audit targets and audit focus also in post-pandemic times. Springer International Publishing 2022-03-09 2022 /pmc/articles/PMC8906112/ /pubmed/35262899 http://dx.doi.org/10.1007/s43441-022-00388-y Text en © The Drug Information Association, Inc 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Analytical Report Koneswarakantha, Björn Ménard, Timothé Statistical Modeling for Quality Risk Assessment of Clinical Trials: Follow-Up at the Era of Remote Auditing |
title | Statistical Modeling for Quality Risk Assessment of Clinical Trials: Follow-Up at the Era of Remote Auditing |
title_full | Statistical Modeling for Quality Risk Assessment of Clinical Trials: Follow-Up at the Era of Remote Auditing |
title_fullStr | Statistical Modeling for Quality Risk Assessment of Clinical Trials: Follow-Up at the Era of Remote Auditing |
title_full_unstemmed | Statistical Modeling for Quality Risk Assessment of Clinical Trials: Follow-Up at the Era of Remote Auditing |
title_short | Statistical Modeling for Quality Risk Assessment of Clinical Trials: Follow-Up at the Era of Remote Auditing |
title_sort | statistical modeling for quality risk assessment of clinical trials: follow-up at the era of remote auditing |
topic | Analytical Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8906112/ https://www.ncbi.nlm.nih.gov/pubmed/35262899 http://dx.doi.org/10.1007/s43441-022-00388-y |
work_keys_str_mv | AT koneswarakanthabjorn statisticalmodelingforqualityriskassessmentofclinicaltrialsfollowupattheeraofremoteauditing AT menardtimothe statisticalmodelingforqualityriskassessmentofclinicaltrialsfollowupattheeraofremoteauditing |